Back to Market返回行情

LFCR Lifecore Biomedical, Inc.

USHealthcare
$4.75+0.00%ClosedMarket Cap: $178.2M

As of 2026-07-10 16:00

Why LFCR matters now

Lifecore Biomedical, Inc. (LFCR) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.75 with +0.00% on the session and $178.2M in market capitalization; recent performance reads 1-month +26.48% and YTD -32.27%.

The latest financial table shown here is Q3 2026, with revenue of $23.2M, net income of $-15.0M, and EPS of $-0.43. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 5.0%.

The latest indexable market news headline is "Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $6.50; recent insider activity includes Kiper Christopher S filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

9.99

P/S

1.54

EV/EBITDA

-328.28

DCF Value

$-10.23

FCF Yield

5.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

31.2%

Operating Margin

-0.1%

Net Margin

-25.2%

ROE

-176.1%

ROA

-15.1%

ROIC

-0.0%

Financials

PeriodRevenueNet IncomeEPS
Q3 2026$23.2M$-15.0M$-0.43
Q2 2026$44.4M$-8.0M$-0.25
Q1 2026$31.1M$-10.0M$-0.29
Q4 2025$36.4M$-1.1M$-0.06

Analyst Ratings

Consensus

Hold

Target (Consensus)

$6.50

Target (Median)

$6.50

Target Range

$6.50 - $6.50

Strong Buy: 1Buy: 2Hold: 2Sell: 0Strong Sell: 0
Barrington ResearchOutperform
2026-06-16
Barrington ResearchOutperform
2026-04-29
Barrington ResearchOutperform
2026-03-27

Trading Activity

Insider Trades

Kiper Christopher Sdirector, 10 percent owner:
Sell2026-06-08
HOUDE LOVAS KATRINAdirector
Sell2026-06-05
Johnson Paul Harolddirector
Sell2026-06-05
Antunes Humberto Calheirosdirector
Sell2026-06-05
Korenberg Matthew Edirector
Sell2026-06-05

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

1.07

Lifecore Biomedical, Inc. (LFCR) operates as a multifaceted contract development and manufacturing organization (CDMO) with a global presence, conducting business through its various subsidiaries. The company's operations are divided into three core segments: Lifecore, Curation Foods, and Other. The Lifecore division is primarily responsible for the production of pharmaceutical-grade sodium hyaluronate (HA) in bulk quantities. It also handles the formulation and sterile filling of syringes and vials containing injectable medications used to treat diverse medical ailments and conditions. Beyond manufacturing, this segment provides a comprehensive suite of CDMO services to its partners. These include the development of new technologies and formulations, analytical method creation, oversight of material component modifications, execution of pilot and stability studies, validation of manufacturing processes, and the production of materials for clinical trials. This extensive support is offered for both HA-based and non-HA products that necessitate aseptic formulation and filling. Furthermore, the Lifecore segment markets its non-HA medical offerings mainly to the ophthalmic (eye care), orthopedic (bone and joint), and other specialized healthcare sectors. The Curation Foods segment focuses on the production, marketing, and distribution of food products. This includes olive oils and wine vinegars sold under the "O" brand, as well as guacamole and avocado-based items available under the "Yucatan" and "Cabo Fresh" brands, in addition to various private label agreements. Established in 1986, the company was formerly known as Landec Corporation before officially rebranding as Lifecore Biomedical, Inc. in November 2022. Its corporate headquarters are situated in Santa Maria, California.